UA109868C2 - Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) - Google Patents

Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)

Info

Publication number
UA109868C2
UA109868C2 UAA201500428A UAA201500428A UA109868C2 UA 109868 C2 UA109868 C2 UA 109868C2 UA A201500428 A UAA201500428 A UA A201500428A UA A201500428 A UAA201500428 A UA A201500428A UA 109868 C2 UA109868 C2 UA 109868C2
Authority
UA
Ukraine
Prior art keywords
compounds
alkyltriazole
asr
disorders
substituents
Prior art date
Application number
UAA201500428A
Other languages
English (en)
Ukrainian (uk)
Inventor
Стівен Дімс Гебріель
Метью Майкл Гамільтон
Метью С. Лукас
Імінь Цянь
Ачютарао Сіддурі
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA109868(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA109868C2 publication Critical patent/UA109868C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Abstract

В данном изобретении предложены соединения формулы (I): EMBED ISISServer , а также их фармацевтически приемлемые соли, где заместители являются такими, как раскрыто в описании. Данные соединения и фармацевтические композиции, которые их содержат, полезны для лечения воспалительных заболеваний и расстройств, таких как, например, фиброз легких.
UAA201500428A 2012-06-20 2013-06-17 Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) UA109868C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20
PCT/EP2013/062461 WO2013189864A1 (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
UA109868C2 true UA109868C2 (ru) 2015-10-12

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201500428A UA109868C2 (ru) 2012-06-20 2013-06-17 Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)

Country Status (22)

Country Link
US (1) US9321738B2 (ru)
EP (1) EP2864300A1 (ru)
JP (1) JP2015520202A (ru)
KR (1) KR20150021057A (ru)
CN (1) CN104411692A (ru)
AU (1) AU2013279512A1 (ru)
BR (1) BR112014030685A2 (ru)
CA (1) CA2869541A1 (ru)
CL (1) CL2014003243A1 (ru)
CO (1) CO7131358A2 (ru)
CR (1) CR20140525A (ru)
EA (1) EA201492285A1 (ru)
HK (1) HK1206342A1 (ru)
IL (1) IL236088A0 (ru)
IN (1) IN2014DN09348A (ru)
MA (1) MA37764A1 (ru)
MX (1) MX2014014710A (ru)
PE (1) PE20142448A1 (ru)
PH (1) PH12014502789A1 (ru)
SG (1) SG11201407220YA (ru)
UA (1) UA109868C2 (ru)
WO (1) WO2013189864A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2844982A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
IN2014DN09352A (ru) * 2012-06-20 2015-07-17 Hoffmann La Roche
PT2988743T (pt) 2013-03-15 2021-03-03 Epigen Biosciences Inc Compostos heterocíclicos úteis no tratamento da doença
RU2689315C2 (ru) 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
EP3728216B1 (en) 2017-12-19 2023-09-06 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
CN112055710A (zh) 2017-12-19 2020-12-08 百时美施贵宝公司 作为lpa拮抗剂的环己基酸吡唑吖嗪
EP3728223B1 (en) * 2017-12-19 2022-12-28 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
JP2021506878A (ja) * 2017-12-19 2021-02-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸
JP7301840B2 (ja) 2017-12-19 2023-07-03 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸
TW201927778A (zh) * 2017-12-19 2019-07-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑唑類
CN112041029A (zh) 2017-12-19 2020-12-04 百时美施贵宝公司 作为lpa拮抗剂的环己基酸吡唑唑类
JP7369125B2 (ja) * 2017-12-19 2023-10-25 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸
CN112521368B (zh) * 2017-12-19 2023-12-05 百时美施贵宝公司 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸
CN112074515A (zh) 2017-12-19 2020-12-11 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类
AR114070A1 (es) * 2017-12-29 2020-07-15 Biomarin Pharm Inc Inhibidores de glicolato oxidasa para el tratamiento de una enfermedad
JP7412424B2 (ja) * 2018-09-18 2024-01-12 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのオキサビシクロ酸
WO2020060916A1 (en) * 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
SG190417A1 (en) * 2010-12-07 2013-07-31 Amira Pharmaceuticals Inc Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
CA2844982A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
CN104411692A (zh) 2015-03-11
US20150133511A1 (en) 2015-05-14
IL236088A0 (en) 2015-02-01
MA37764A1 (fr) 2016-01-29
WO2013189864A1 (en) 2013-12-27
IN2014DN09348A (ru) 2015-07-17
JP2015520202A (ja) 2015-07-16
CO7131358A2 (es) 2014-12-01
US9321738B2 (en) 2016-04-26
SG11201407220YA (en) 2014-12-30
AU2013279512A1 (en) 2014-10-16
PE20142448A1 (es) 2015-01-28
PH12014502789A1 (en) 2015-02-09
HK1206342A1 (en) 2016-01-08
CR20140525A (es) 2015-01-12
CA2869541A1 (en) 2013-12-27
EA201492285A1 (ru) 2015-04-30
BR112014030685A2 (pt) 2017-06-27
EP2864300A1 (en) 2015-04-29
CL2014003243A1 (es) 2015-03-20
KR20150021057A (ko) 2015-02-27
MX2014014710A (es) 2015-03-04

Similar Documents

Publication Publication Date Title
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
IN2014DN09347A (ru)
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MX2015017964A (es) Inhibidores de bromodominio.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
PH12015501609A1 (en) Phenicol antibacterials
IN2015DN01119A (ru)
MX2016002794A (es) Compuestos antiproliferativos.
MY183974A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2013040227A3 (en) Therapeutic compounds
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MY191352A (en) Aldosterone synthase inhibitors
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.